Successful completion of integrative oncology trial
Marinova is pleased to announce the successful completion of an integrative oncology trial involving one of its lead fucoidan products. A collaboration between Marinova, the School of Pharmacy at the University of Tasmania and the Royal Hobart Hospital, the trial assessed whether there was any interaction between Maritech® Undaria fucoidan and conventional hormone therapies in breast cancer patients. Maritech® fucoidan was administered orally at a dosage of 1 g/day for three weeks to patients undergoing treatment for an active malignancy with letrozole or tamoxifen. Blood samples were taken at the start and conclusion of the trial and plasma concentrations of letrozole or tamoxifen were analysed. The study was overseen by Professors Ray Lowenthal and Greg Peterson and conducted over a 2 year period with candidates completing their participation in late 2014.
Results from the clinical trial are currently being collated with journal publication expected later in 2015.